President Donald Trump launched TrumpRx.gov earlier this month to lower the cost of many popular medicines by offering prices typically found in other developed countries. The White House says the ...

The biotech company said its multi-cancer screening test Galleri did not lead to a “statistically significant reduction” in ...

GRAIL (GRAL) stock plunges after NHS-Galleri trial miss for Galleri cancer test, which was added to the Hims & Hers (HIMS) platform earlier this month. Read more here.

So-called "savings" of government interference in medicine come at the expense of access to doctors, diagnostics, and ...

Easier than a blood test, saliva tests have the potential to detect cavities, infections and even cancer. But a lack of ...

Grail shares plunged nearly 50% in premarket trading on Friday after its three-year cancer screening trial failed to meet its main goal, dealing a major blow to the blood test maker.

At Fierce Healthcare, we keep track of all the venture capital being funneled into the health tech and digital health industries. | Keep up with all the venture capital dollars being funneled into the ...

CMS isn’t just tweaking ASC policies in 2026; it’s remolding the financial and regulatory foundation of outpatient surgery. From a major expansion of procedures allowed in the setting to the phaseout ...

The current quarter saw the announcement of an increased five-year investment plan ($24 billion vs. $20 billion previously) and higher adjusted EPS guidance for 2026 ($3.83–$3.90 vs. prior $3.80–$3.87 ...

DISCLAIMER: This site and the products offered are for entertainment purposes only, and there is no gambling offered on this site. This service is intended for adult audiences. No guarantees are made ...